Cellectis S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andre Choulika
- Full Time Employees
- 229
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8, rue de la Croix Jarry Paris IF France 75013
- IPO Date
- Mar 24, 2015
- CIK
- 0001627281
- Website
- cellectis.com
- Similar Companies
- Business
- Cellectis S.A. (Nasdaq: CLLS; Euronext Growth: ALCLS) is a clinical-stage biopharmaceutical company focused on gene-edited allogeneic CAR T-cell immunotherapies for cancer using its proprietary TALEN gene-editing technology and PulseAgile electroporation system; core product candidates include lasme-cel (UCART22) for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), eti-cel (UCART20x22) for relapsed/refractory non-Hodgkin lymphoma (r/r NHL), and earlier-stage UCARTs targeting hematologic malignancies such as acute myeloid leukemia; the company pioneered off-the-shelf allogeneic CAR T-cells from healthy donors, enabling scalable, standardized manufacturing distinct from patient-specific autologous therapies. Founded in 1999 and headquartered at 8 Rue de la Croix Jarry in Paris, France, with additional facilities in New York, New York, and Raleigh, North Carolina, Cellectis operates primarily in the United States and Europe, targeting patients with high unmet needs in oncology through clinical trials and strategic manufacturing sites for plasmids, mRNA, viral vectors, and GMP UCART production. Recent developments include positive Phase 1 data for lasme-cel showing 68% overall response rate (83% at recommended Phase 2 dose) and median overall survival of 14.8 months in MRD-negative responders, with pivotal Phase 2 interim analysis expected in Q4 2026 and BLA submission in 2028; encouraging eti-cel results with 86% ORR and 57% complete response rate in r/r NHL, full Phase 1 data due in 2026; a 2023 strategic collaboration and investment with AstraZeneca involving up to $140 million equity and joint R&D for 10 cell/gene therapy programs in oncology, immunology, and rare diseases, yielding $47 million by end-2024; ongoing Servier arbitration decision expected by December 15, 2025; and advancements in non-viral CssDNA templates and TALEB base editors presented at ESGCT 2025.
Company News
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Monthly information on share capital and company voting rights
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Cellectis S.A. (CLLS) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation